Split availability: NAD+ is available through a clinician; MOTS-c and SS-31 are education-only.
The Energy Stack
The energy / mitochondrial stack: NAD+ as the cellular-energy substrate, MOTS-c as a mitochondrial signal, with SS-31 sometimes discussed as an escalation for structural mitochondrial issues.
Last reviewed June 16, 2026.
The honest answer
This is the energy and mitochondrial-support stack: NAD+ as the cellular-energy substrate, MOTS-c as a mitochondrial signal, and SS-31 sometimes raised as an escalation when the bottleneck looks structural. Read it as energy and support, not anti-aging. One member, NAD+, is available through a clinician; the others are education only.
- NAD+ is the universal ‘energy floor’ people reach for.
- MOTS-c is an early-stage mitochondrial-derived peptide studied for AMPK / metabolic signaling.
- This is energy-and-support territory, not anti-aging, no lifespan, anti-aging, or disease-cure claims for any of these.
- SS-31 (elamipretide) has an FDA accelerated approval for a rare condition (Barth syndrome) only, that is not approval for general energy or longevity use.
Go deeper
The concept is a ladder: NAD+ as the energy substrate, MOTS-c as an adaptive mitochondrial signal, and SS-31 as an escalation when the limitation looks structural rather than just low fuel. It's framed around cellular energy and support. Nothing here is an anti-aging plan, and how any of it is used is a clinical decision, not a protocol.
We describe these in terms of energy and support. We don't claim they slow aging, extend lifespan, or treat disease.
Status & access
NAD+ is available through a clinician and routes to a plan. MOTS-c is education-only; SS-31 (elamipretide) is approved for Barth syndrome only, not for energy or longevity, and is education-only here. We describe all of this in terms of energy and support, never anti-aging.
Compounded medications are prepared for an individual patient and are not FDA-approved. Removal from FDA Category 2 (April 2026) is not approval and not 503A Bulks-List eligibility. PCAC is advisory, a favorable vote leads to rulemaking, not instant availability.
We describe these in terms of energy and support. We don't claim they slow aging, extend lifespan, or treat disease.
Questions, answered first
What is the NAD+ MOTS-c stack?
It's the energy/mitochondrial stack: NAD+ as the cellular-energy substrate and MOTS-c as a mitochondrial signal, sometimes with SS-31 discussed as an escalation. We treat it as energy and support, NAD+ is available through a clinician; MOTS-c and SS-31 are education only.
Is NAD+ anti-aging?
We don't make that claim. NAD+ is involved in how cells produce and use energy, and we describe it in terms of energy and cellular support, not lifespan extension, anti-aging, or disease treatment. The longevity evidence in humans is still emerging.
Is SS-31 / elamipretide available?
Not for energy or longevity. SS-31 (elamipretide) received an FDA accelerated approval for a rare condition, Barth syndrome, only. That approval is not a clearance for general energy or anti-aging use, so we keep it education-only and never imply otherwise.